来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02105 来凯医药-B

休市中 07-26 16:08:20

4.090

+0.010

+0.25%

最高4.160	最低3.900	成交量34.90万
今开3.930	昨收4.080	日振幅6.37%
总市值15.96亿	流通市值15.96亿	总股本3.90亿
成交额142.11万	换手率0.09%	流通股本3.90亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02105","market":"HK","secType":"STK","nameCN":"来凯医药-B","latestPrice":4.09,"timestamp":1721981300025,"preClose":4.08,"halted":0,"volume":349000,"delay":0,"floatShares":390100350,"shares":390100350,"eps":-1.8063068,"marketStatus":"休市中","marketStatusCode":7,"change":0.01,"latestTime":"07-26 16:08:20","open":3.93,"high":4.16,"low":3.9,"amount":1421130,"amplitude":0.063725,"askPrice":4.09,"askSize":10500,"bidPrice":4.08,"bidSize":2500,"shortable":0,"etf":0,"ttmEps":-1.806306813777382,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1722216600000},"adr":0,"listingDate":1687968000000,"adjPreClose":4.08,"openAndCloseTimeList":[[1721957400000,1721966400000],[1721970000000,1721980800000]],"volumeRatio":0.3586107686094927,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02105/wiki","defaultTab":"wiki","newsList":[{"id":"2453008277","title":"来凯医药-B07月23日主力资金流出27万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2453008277","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453008277?lang=zh_cn&edition=full","pubTime":"2024-07-23 16:16","pubTimestamp":1721722593,"startTime":"0","endTime":"0","summary":"07月23日, 来凯医药-B股价跌4.74%，报收4.22元，成交金额316万元，换手率0.19%，振幅7.90%，量比0.57。来凯医药-B今日主力资金净流出27万元，连续5日净流出，上一交易日主力净流出108万元，今日环比减少75.00%。近一年数据显示，该股主力连续5日净流出后，次日下跌概率为66.67%，平均跌幅为10.72%。该股近5个交易日下跌13.67%，主力资金累计净流出192万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出232万元，其中净流出天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072316173095526415&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072316173095526415&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2453924759","title":"来凯医药-B07月22日遭主力抛售108万元 环比增加3500.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453924759","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453924759?lang=zh_cn&edition=full","pubTime":"2024-07-22 16:15","pubTimestamp":1721636116,"startTime":"0","endTime":"0","summary":"07月22日, 来凯医药-B股价涨3.02%，报收4.43元，成交金额605万元，换手率0.35%，振幅6.98%，量比1.04。来凯医药-B今日主力资金净流出108万元，连续4日净流出，上一交易日主力净流出3万元，今日环比增加3500.00%。近一年数据显示，该股主力连续4日净流出后，次日下跌概率为80.00%，平均跌幅为6.22%。该股近5个交易日下跌14.34%，主力资金累计净流出166万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出206万元，其中净流出天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407221615269ede5b4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407221615269ede5b4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2452556532","title":"18A市值半年考！君圣泰、圣诺医药跌幅近九成，科伦博泰、复宏汉霖、亚盛医药涨幅前三","url":"https://stock-news.laohu8.com/highlight/detail?id=2452556532","media":"医药经济报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452556532?lang=zh_cn&edition=full","pubTime":"2024-07-20 13:31","pubTimestamp":1721453482,"startTime":"0","endTime":"0","summary":"截至7月19日中午，近半年来，总市值跌幅最大的十家企业分别是君圣泰医药、圣诺医药、健世科技、来凯医药、创胜集团、润迈德、康宁杰瑞制药、宜明昂科、德琪医药和兆科眼科。截至公告发布之日，圣诺医药仅赎回了20万美元。截至7月19日中午，科伦博泰、复宏汉霖、亚盛医药、欧康维视生物和东曜药业近半年总市值","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407201333569f6fe90d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407201333569f6fe90d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02511","09877","06628","09939","01875","02105","02257","BK1161","02696","BK1574","06855","BK1515"],"gpt_icon":0},{"id":"2452449794","title":"来凯医药-B07月19日主力资金流出3万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2452449794","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452449794?lang=zh_cn&edition=full","pubTime":"2024-07-19 16:16","pubTimestamp":1721376998,"startTime":"0","endTime":"0","summary":"07月19日, 来凯医药-B股价跌8.32%，报收4.30元，成交金额787万元，换手率0.46%，振幅8.96%，量比1.42。来凯医药-B今日主力资金净流出3万元，连续3日净流出，上一交易日主力净流出26万元，今日环比减少88.46%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为50.00%，平均跌幅为9.68%。该股近5个交易日下跌20.04%，主力资金累计净流出4万元；近20日主力资金累计净流出98万元，其中净流出天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407191617329f6a65ed&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407191617329f6a65ed&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2452178494","title":"来凯医药－Ｂ(02105)股价下跌8.316%，现价港币$4.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2452178494","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452178494?lang=zh_cn&edition=full","pubTime":"2024-07-19 14:40","pubTimestamp":1721371200,"startTime":"0","endTime":"0","summary":"[下跌股]来凯医药－Ｂ(02105) 股价在下午02:40比前收市价下跌8.316%，现股价为港币$4.3。至目前为止，今日最高价为$4.65，而最低价为$4.3。总成交量为101.25万股，总成交金额为港币$449.482万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126135510179_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2407193736/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2450885307","title":"来凯医药-B午后涨近5% ActRIIA单抗LAE102治疗肥胖临床获中美批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2450885307","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450885307?lang=zh_cn&edition=full","pubTime":"2024-07-10 14:39","pubTimestamp":1720593564,"startTime":"0","endTime":"0","summary":"来凯医药-B（02105）午后上涨4.58%，现报5.02港元，成交额1154.85万港元。\n　　6月26日，来凯医药宣布已在中国启动了LAE102的I期临床试验招募，并已完成首例受试者用药。在临床前模型中，LAE102已显示出增加肌肉并减少脂肪的效果。据悉，今年上半年，LAE102已分别获得美国FDA和中国CDE针对肥胖适应症的新药临床试验（IND）批准。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-10/doc-inccrsee9510281.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-07-10/doc-inccrsee9510281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2450185843","title":"港股异动 | 来凯医药-B(02105)午后急涨逾10% ActRIIA单抗LAE102治疗肥胖临床获中美批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2450185843","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450185843?lang=zh_cn&edition=full","pubTime":"2024-07-10 14:12","pubTimestamp":1720591954,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B午后急涨逾10%，截至发稿，涨4.79%，报5.03港元，成交额1065.49万港元。消息面上，6月26日，来凯医药宣布已在中国启动了LAE102的I期临床试验招募，并已完成首例受试者用药。在临床前模型中，LAE102已显示出增加肌肉并减少脂肪的效果。据悉，今年上半年，LAE102已分别获得美国FDA和中国CDE针对肥胖适应症的新药临床试验批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148447.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07226","02105","HSCEI","HSTECH","YANG"],"gpt_icon":0},{"id":"2450830309","title":"来凯医药－Ｂ(02105)股价上升5%，现价港币$5.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2450830309","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450830309?lang=zh_cn&edition=full","pubTime":"2024-07-10 13:37","pubTimestamp":1720589820,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药－Ｂ(02105) 股价在下午01:37比前收市价上升5%，现股价为港币$5.04。至目前为止，今日最高价为$5.04，而最低价为$4.75。总成交量为60.8万股，总成交金额为港币$299.827万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2407102337/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2446142465","title":"来凯医药-B现涨逾10% 已在中国启动了LAE102的I期临床试验招募","url":"https://stock-news.laohu8.com/highlight/detail?id=2446142465","media":"新浪港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446142465?lang=zh_cn&edition=full","pubTime":"2024-06-28 09:52","pubTimestamp":1719539574,"startTime":"0","endTime":"0","summary":"来凯医药-B（02105）早盘最高涨超12%，涨幅现收窄至上涨9.96%，报5.63港元，成交额527.029万港元。\n　　6月26日，来凯医药宣布已在中国启动了LAE102的I期临床试验招募，并已完成首例受试者用药。在临床前模型中，LAE102已显示出增加肌肉并减少脂肪的效果。据悉，今年上半年，LAE102已分别获得美国FDA和中国CDE针对肥胖适应症的新药临床试验（IND）批准。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-28/doc-incafxzp4694068.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-06-28/doc-incafxzp4694068.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1583","BK1161","BK1141","03347","02105","BK1576"],"gpt_icon":0},{"id":"2446511141","title":"港股异动 | 来凯医药-B(02105)最高涨超12% 与诺和诺德“增肌减脂”合作研究引发关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2446511141","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446511141?lang=zh_cn&edition=full","pubTime":"2024-06-28 09:44","pubTimestamp":1719539095,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B最高涨超12%，截至发稿，涨8.98%，报5.58港元，成交额449.12万港元。来凯医药目前的核心管线，是其自主研发的ActRIIA单克隆抗体LAE102。6月26日，来凯医药宣布已在中国启动了LAE102的I期临床试验招募，并已完成首例受试者用药。在临床前模型中，LAE102已显示出增加肌肉并减少脂肪的效果。据悉，今年上半年，LAE102已分别获得美国FDA和中国CDE针对肥胖适应症的新药临床试验批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1142192.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07226","NVO","BK4007","HSTECH","BK4532","02105","IE00BZ1G4Q59.USD","HSCEI","BK4588","IE00BKVL7J92.USD","BK1161","YANG","BK4585"],"gpt_icon":0},{"id":"2446518610","title":"“增肌减脂”成千亿减重市场新热门，来凯医药-B(02105)与诺和诺德“增肌减脂”合作研究引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2446518610","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446518610?lang=zh_cn&edition=full","pubTime":"2024-06-28 08:27","pubTimestamp":1719534423,"startTime":"0","endTime":"0","summary":"正因如此，“增肌减脂”成为减重药物领域的热门研究方向。而来凯医药自主研发的LAE102主要针对参与调控肌肉再生和脂代谢的新靶点ActRIIA。在此前的临床前研究中，LAE102已显示出增加肌肉并减少脂肪的效果。此次，来凯医药与诺和诺德的合作研究引发了业界与市场的广泛讨论与猜测。市场关注的点在于，诺和诺德与来凯医药的合作是否将从研究端延伸至产品端。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406280829559f6da9fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406280829559f6da9fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02105","NVO"],"gpt_icon":0},{"id":"2446438694","title":"高质量创新成为国产药品开发主旋律，港股创新药ETF(159567)跟踪指数走势占优，中国生物制药、君实生物、来凯医药-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446438694","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446438694?lang=zh_cn&edition=full","pubTime":"2024-06-26 10:41","pubTimestamp":1719369706,"startTime":"0","endTime":"0","summary":"2024年6月26日，港股创新药板块领跑港股市场。盘面上，中国生物制药领涨，君实生物、来凯医药-B跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额高达5977万元。国联证券表示，高质量创新成为国产药品开发主旋律。进入2024年，创新药首发定价征求意见稿和各地创新药全产业链支持政策文件的出台充分体现了国家对高质量创新药研发的鼓励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406261041509f660336&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","688180","01177","BK1589","02105","BK1583","BK1191","BK1161","BK1521","01877"],"gpt_icon":0},{"id":"2446807645","title":"港股异动 | 来凯医药-B(02105)高开逾7% LAE102肥胖症I期临床试验完成首例受试者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2446807645","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446807645?lang=zh_cn&edition=full","pubTime":"2024-06-26 09:22","pubTimestamp":1719364939,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B高开逾7%，截至发稿，涨7.17%，报5.98港元，成交额33.49万港元。消息面上，来凯医药公布，集团已在中国启动了LAE102的I期临床试验招募，并已完成首例受试者用药。该I期临床试验是一项随机、双盲、安慰剂对照研究，旨在评估该疗法的安全性、耐受性以及药代动力学。据悉，在临床前模型中，LAE102已显示出增加肌肉并减少脂肪的效果。2024年上半年，LAE102分别获得美国FDA和中国CDE针对肥胖适应症的新药临床试验批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140561.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["YANG","03347","BK1583","BK1141","BK1161","HSCEI","07226","HSTECH","BK1576","02105"],"gpt_icon":0},{"id":"2446801745","title":"来凯医药(02105.HK)治疗肥胖症药物临床试验完成首例受试者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2446801745","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446801745?lang=zh_cn&edition=full","pubTime":"2024-06-26 08:38","pubTimestamp":1719362280,"startTime":"0","endTime":"0","summary":"来凯医药(02105.HK) 公布，已在中国启动LAE102针对肥胖症治疗的I期临床试验招募，并已完成首例受试者用药。该I期临床试验是一项随机、双盲、安慰剂对照研究，旨在评估该疗法的安全性、耐受性以及药代动力学。LAE102是针对ActRIIA的单克隆抗体，ActRIIA是在肌肉再生和脂肪代谢中发挥重要作用的受体。(jl/cy)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"us","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20230904154158726_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20230904154158726_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1359155/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02105","BK1141","BK1576","BK1583","03347","BK1161"],"gpt_icon":0},{"id":"2446806457","title":"来凯医药-B(02105)：LAE102针对肥胖症治疗的I期临床试验完成首例受试者用药","url":"https://stock-news.laohu8.com/highlight/detail?id=2446806457","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446806457?lang=zh_cn&edition=full","pubTime":"2024-06-26 08:03","pubTimestamp":1719360223,"startTime":"0","endTime":"0","summary":"智通财经APP讯，来凯医药-B 发布公告，集团已在中国启动了LAE102的I期临床试验招募，并已完成首例受试者用药。据悉，LAE102是针对ActRIIA的单克隆抗体，ActRIIA是在肌肉再生和脂肪代谢中发挥重要作用的受体。在临床前模型中，LAE102已显示出增加肌肉并减少脂肪的效果。LAE102与GLP-1受体激动剂联用可进一步减少脂肪并显著降低GLP-1受体激动剂导致的肌肉流失，使LAE102成为一种高质量体重控制候选药物，在减脂的同时保持肌肉质量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1140542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1583","BK1161","BK1141","02105","BK1576"],"gpt_icon":0},{"id":"2446277861","title":"创新药板块催化频出，港股创新药ETF(159567)跟踪指数走势较强，云顶新耀-B、来凯医药-B、翰森制药领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2446277861","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446277861?lang=zh_cn&edition=full","pubTime":"2024-06-25 14:21","pubTimestamp":1719296513,"startTime":"0","endTime":"0","summary":"2024年6月25日，港股创新药板块走势占优。盘面上，云顶新耀-B领涨，来凯医药-B、翰森制药跟涨，港股创新药ETF市场热度较高，过去5个交易日日均成交额6447万元。受益于个股业绩超预期海内外新药研发数据优秀等利好催化，减重药、艾滋病预防用药、脑机接口等热点主题表现相对活跃。当前医药生物板块整体表现持续低迷，市场情绪有待恢复，建议以中长线视角布局高景气细分领域投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062514215595d55b32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024062514215595d55b32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","BK1589","BK1574","02105","BK1583","BK1191","03692","01952"],"gpt_icon":0},{"id":"2446852619","title":"港股异动 | 来凯医药-B(02105)涨超12% 核心管线具备多项催化剂 “增肌减脂”管线研发加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2446852619","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446852619?lang=zh_cn&edition=full","pubTime":"2024-06-25 11:29","pubTimestamp":1719286197,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B最高涨超12%，截至发稿，涨10.9%，报5.9港元，成交额432.4万港元。消息面上，来凯医药上月宣布，继获美国FDA新药临床试验批准后，其自主研发的LAE102已获得国家药监局药品审评中心的IND批准，用于治疗肥胖症患者。据悉，近年来，以司美格鲁肽为首的GLP-1靶点减肥药席卷全市场。2024年，减肥药概念热度依旧高涨。此外，太平洋证券指出，2024年公司核心管线具有多项催化剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1139960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSTECH","07226","BK1161","YANG","02105","HSCEI"],"gpt_icon":0},{"id":"2446852978","title":"来凯医药－Ｂ(02105)股价显著上升12.406%，现价港币$5.98","url":"https://stock-news.laohu8.com/highlight/detail?id=2446852978","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446852978?lang=zh_cn&edition=full","pubTime":"2024-06-25 11:24","pubTimestamp":1719285840,"startTime":"0","endTime":"0","summary":"[上升股]来凯医药－Ｂ(02105) 股价在上午11:24比前收市价显著上升12.406%，现股价为港币$5.98。至目前为止，今日最高价为$5.98，而最低价为$5.38。总成交量为29.9万股，总成交金额为港币$166.835万。","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180205152552334_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2406251370/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02105"],"gpt_icon":0},{"id":"2445045708","title":"来凯医药－Ｂ(02105)股价下跌6.702%，现价港币$5.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2445045708","media":"阿斯达克财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445045708?lang=zh_cn&edition=full","pubTime":"2024-06-24 15:04","pubTimestamp":1719212640,"startTime":"0","endTime":"0","summary":"[下跌股]来凯医药－Ｂ(02105) 股价在下午03:04比前收市价下跌6.702%，现股价为港币$5.29。至目前为止，今日最高价为$5.7，而最低价为$5.29。总成交量为37.25万股，总成交金额为港币$208.154万。","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725131622959_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2406242310/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02105","BK1161"],"gpt_icon":0},{"id":"2444346002","title":"国内药企入选ASCO口头报告数量创新高，港股创新药ETF(159567)跟踪指数逆市上涨，复星医药、荣昌生物、来凯医药-B领涨。","url":"https://stock-news.laohu8.com/highlight/detail?id=2444346002","media":"有连云","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444346002?lang=zh_cn&edition=full","pubTime":"2024-06-20 10:21","pubTimestamp":1718850105,"startTime":"0","endTime":"0","summary":"2024年6月20日，港股创新药板块逆市大涨。广发证券表示，国内药企入选ASCO口头报告数量创新高。入选ASCO大会口头报告的国内药企数量创新高，体现了我国整体新药研发能力逐渐获得国际的认可，多家药企在大会展示了亮眼的数据，建议关注产品数据超预期或有成为best in class潜力的国内药企。国内创新药已进入收获期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406201021489f5096d4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202406201021489f5096d4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02105","02196","BK1593","LU1969619763.USD","BK1515","BK1191","BK1583","BK1574","688331","600196","LU2328871848.SGD","09995","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.laekna.com","stockEarnings":[{"period":"1week","weight":-0.0488},{"period":"1month","weight":-0.2722},{"period":"3month","weight":-0.3382},{"period":"6month","weight":-0.479},{"period":"1year","weight":-0.6993},{"period":"ytd","weight":-0.7945}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0591},{"period":"3month","weight":-0.0357},{"period":"6month","weight":0.067},{"period":"1year","weight":-0.1333},{"period":"ytd","weight":-0.0015}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"来凯医药有限公司是一家主要从事癌症及肝脏疾病创新疗法的发现、开发及商业化的投资控股公司。该公司主要从事单药疗法及联合疗法的候选药物的研发，专注用于治疗各种癌症及肝纤维化疾病。该公司的主要产品管线包括LAE002及LAE001。LAE002是一种三磷酸腺苷（ATP）竞争性AKT抑制剂，用于治疗卵巢癌、前列腺癌、乳腺癌及PD-1/PD-L1耐药实体瘤。LAE001是雄激素合成抑制剂，可同时抑制细胞色素P450家族17亚族A成员1（CYP17A1）及细胞色素P450家族11亚族B成员2（CYP11B2），用于治疗前列腺癌。该公司主要在中国、美国、欧洲及韩国市场开展业务。","exchange":"SEHK","name":"来凯医药-B","nameEN":"LAEKNA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"来凯医药-B,02105,来凯医药-B股票,来凯医药-B股票老虎,来凯医药-B股票老虎国际,来凯医药-B行情,来凯医药-B股票行情,来凯医药-B股价,来凯医药-B股市,来凯医药-B股票价格,来凯医药-B股票交易,来凯医药-B股票购买,来凯医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"来凯医药-B(02105)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供来凯医药-B(02105)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}